Game-Changer In Epidermolysis Bullosa Treatment? Cannabis Compound Holds Promise
Portfolio Pulse from Javier Hasse
InMed Pharmaceuticals Inc. (NASDAQ:INM) has published positive top-line data from its INM-755 Phase II study for the treatment of epidermolysis bullosa (EB), a rare genetic dermatological condition. The study supports further development of the cannabinol-based topical skin cream, INM-755. Following the data, InMed is exploring commercial partnerships for further development and distribution of the cream. The company is also open to early monetization opportunities through the sale or out-licensing of the program.
July 07, 2023 | 3:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InMed Pharmaceuticals' positive Phase II data for its EB treatment, INM-755, could potentially attract commercial partnerships for further development and distribution. This could ease the financial burden on InMed and allow more resources to be allocated to other programs.
The positive Phase II data for InMed's INM-755 treatment for EB is a significant milestone for the company. This could potentially attract commercial partnerships for further development and distribution of the treatment, which would ease the financial burden on InMed and allow more resources to be allocated to other programs. This is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100